Table 5.

Multivariate regression analysis for risk factors of NAFLD (n = 868)

	B	S.E.	Wald	df	Sig.	Exp(B)	95.0% CI.for EXP(B)
							Lower	Upper
Gender	0.822	0.447	3.381	1	0.066	2.274	0.947	5.459
Age	0.011	0.016	0.450	1	0.502	1.011	0.980	1.042
rs10865710*	−0.601	0.243	6.097	1	0.014	1.824	1.132	2.940
rs7649970*	15.782	1.72E4	0.000	1	0.999	7.14E6	0.000	-
rs1801282*	−15.905	1.72E4	0.000	1	0.999	0.000	0.000	-
BMI	0.567	0.074	57.856	1	0.000	1.762	1.523	2.039
SBP	0.000	0.013	0.000	1	0.985	1.000	0.975	1.025
DBP	0.014	0.023	0.397	1	0.529	1.014	0.970	1.061
FBG	0.236	0.103	5.278	1	0.022	1.266	1.035	1.547
ALT	0.076	0.015	26.696	1	0.000	1.079	1.049	1.111
TG	0.238	0.118	4.079	1	0.043	1.269	1.007	1.599
HDLc	−0.048	0.127	0.143	1	0.705	0.953	0.743	1.223
MS	1.270	0.373	11.597	1	0.001	3.560	1.714	7.395
HOMA-IR	−0.273	0.116	5.532	1	0.019	0.761	0.606	0.956
GGT	0.011	0.010	1.170	1	0.279	1.011	0.991	1.031
ALP	0.003	0.006	0.197	1	0.657	1.003	0.990	1.016
TC	0.220	0.164	1.797	1	0.180	1.246	0.903	1.718
FINS	0.135	0.055	6.126	1	0.013	1.144	1.028	1.274

B, the values for the logistic regression equation for predicting the dependent variables from the independent variables; S.E., the standard errors associated with the coefficients; Wald and Sig., the Wald chi-square value and 2-tailed p-value used in test; df, the degrees of freedom for each of the tests of the coefficients; Exp(B), the odds ratios for the predictors

ALP, alkaline phosphatase ; ALT, alanine transaminase; BMI, body mass index; DBP, diastolic blood pressure; FINS, fasting insulin; FPG, fasting plasma glucose; GGT, gamma-glutamyl transpeptidase; HDLc, high-density lipoprotein cholesterol; HOMA-IR, homoeostatic metabolic assessment insulin resistance index; MS, metabolic syndrome; NAFLD, non-alcoholic fatty liver disease; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride

^*rs10865710=C-681G; rs7649970=C-689T; rs1801282=Pro12Ala